This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Neurocrine Says Sleeping Pill Data Are Good





Neurocrine Biosciences (NBIX) said Thursday that results from the first late-stage study of its experimental sleeping pill proved the drug to be effective and safe in patients with transient insomnia.

Results from the 593-patient, phase III clinical trial demonstrated that a capsule formulation of the drug Indiplon allowed people to fall asleep quickly without feeling drowsy the following day. The study achieved statistically significant results in both its primary and secondary endpoints, which used machines to measure objectively the onset and quality of a person's sleep.

In addition to this study, Neurocrine is currently conducting four additional phase III clinical trials with the capsule formulation of Indiplon and three phase III trials with a tablet form of the drug. The studies will be used to eventually support an approval application for multiple indications associated with insomnia.

If approved, Indiplone will compete against prescription sleeping pills such as Ambien, which is marketed by Sanofi-Synthelabo (SNY).

Neurocrine is expected soon to hammer out a comarketing deal with a major pharmaceutical maker.

Shares of Neurocrine closed Wednesday at $46.29.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
NBIX $42.49 0.00%
SYN $2.36 0.00%
AAPL $124.75 0.00%
FB $80.78 0.00%
GOOG $524.05 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs